Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies

Jianwei Zhang; Xiaoyu Xie; Zehua Wu; Huabin Hu; Yue Cai; Jianxia Li; Jiayu Ling; Miaomiao Ding; Weiwei Li; Yanhong Deng

doi:10.1016/j.clcc.2021.06.004

Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies

Clin Colorectal Cancer. 2021 Dec;20(4):e240-e248. doi: 10.1016/j.clcc.2021.06.004. Epub 2021 Jun 26.

Authors

Jianwei Zhang¹, Xiaoyu Xie¹, Zehua Wu¹, Huabin Hu¹, Yue Cai¹, Jianxia Li¹, Jiayu Ling¹, Miaomiao Ding¹, Weiwei Li¹, Yanhong Deng²

Affiliations

¹ Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, Guangdong, P.R. China.
² Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P.R. China.; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, Guangdong, P.R. China. Electronic address: dengyanh@mail.sysu.edu.cn.

PMID: 34334298
DOI: 10.1016/j.clcc.2021.06.004

Abstract

Purpose: To evaluate the predictive implications and prognosis of mucinous adenocarcinoma (MAC) in locally advanced rectal cancer (LARC) with intensified neoadjuvant treatment.

Methods: Individual patient data of LARC patients from 3 prospective clinical trials was analyzed. Neoadjuvant treatment regimens comprised chemoradiotherapy (CRT) with fluorouracil (5-FU) or mFOLFOX6, neoadjuvant chemotherapy alone with mFOLFOX6 or mFOLFOXIRI. The postoperative pathological result, local recurrence and disease-free survival (DFS) were retrospectively analyzed in patients with MAC and adenocarcinoma (AC) with neoadjuvant treatment.

Results: Totally, 743 patients were recruited, with 620 patients eligible for analysis. Fifty-three (8.5%) patients were MAC. The pathological complete response (pCR) rate and tumor downstaging rate (ypStage 0-I) between MAC and AC patients was 7.5% vs. 22.0% (P = .01) and 20.8% vs. 48.7% (P < .001), respectively. Among patients receiving preoperative CRT with 5FU or mFOLFOX6, the pCR rate and tumor downstaging rate between MAC and AC patients was 11.1% vs. 27.3% (P = .03) and 23.7% vs. 52.6% (P = .001), respectively. Regarding neoadjuvant chemotherapy alone with mFOLFOX6 or mFOLFOXIRI, the pCR rate and tumor downstaging rate was 0 vs.13.2% (P = .11) and 11.8% vs. 42.5% (P = .03) between MAC and AC group, respectively. With the median follow-up time of 38.9 months, the 3-year DFS and 3-year locoregional recurrence rate was 58.4% vs. 77.6% (P = .02) and 26.0% vs. 5.7% (P = .001) in the MAC and AC group, respectively. MAC (hazard ratio [HR] 1.85, 95% confidence interval [CI], 1.15-2.98), PNI (HR 3.23, 95% CI, 1.85-5.72) and LVI (HR 2.04, 95% CI, 1.02-4.08) were independent prognosis factors and were associated with worse DFS.

Conclusions: Patients with MAC of the rectum are associated with a lower pCR rate and tumor downstaging rate, higher incidence of local recurrence, and poorer DFS with neoadjuvant treatment.

Keywords: Disease-free survival; Local recurrence; Neoadjuvant treatment; Pathological complete redponse; Tumor downstaging.

Publication types

Meta-Analysis
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma, Mucinous* / therapy
Humans
Prognosis
Prospective Studies
Rectal Neoplasms* / therapy
Rectum
Retrospective Studies